Watch for the background materials
doi: 10.3389/fimmu.2014.00603 186 RiksenNP
The single most important fact to state at the outset is this: no head-to-head trial human or animal has ever compared BPC-157 against TB-500
Glutathione S-transferase P1 *C allelic variant increases susceptibility for late-onset Alzheimer disease: association study and relationship with apolipoprotein E epsilon4 allele
GHK-Cu adds structural stability by enhancing collagen matrix integrity
GSH augmentation deserves investigation as a beneficial therapeutic approach for not only PD but also numerous other CNS disorders for which GSH deficiency and GSH-related enzyme deficits have been documented (multiple sclerosis, 25,26 autism, 2729 Alzheimers disease, 30,31 schizophrenia, 32,33 and bipolar disease 34 )